For 122 of these patients, this indication was based only on tumour size or on the combination of tumour size and Her2Neu receptor status, grade or age; for 71 patients, the indication was based both on tumour characteristics and on positive lymph nodes, and for 42 patients, it was based only on positive lymph nodes. The gene discussed is ERBB2; the disease is neoplasm.